hemodynamic energy significantly increased, respectively, to 1.05 and 1346 ergs/cm at ±15% speed modulation and to 1.51 and 3381 ergs/cm at ±25% speed modulation. This study showed that it is feasible to generate pressure pulsatility with pump speed modulation; the platform is suitable for evaluating the physiologic impact of pulsatility and allows determination of the best speed modulations in terms of magnitude, frequency, and profiles.
Introduction
Over the past several years, continuous-flow (CF) left ventricular-assist devices (LVADs), which are either axial or centrifugal in design, have replaced volume-displacement pulsatile-flow pumps because of their simplicity, mechanical reliability, durability, small size, patient, and caregiver acceptability, and improved outcomes. However, in patients with a CFLVAD, there have been increasing reports of the incidence of multiple complications, such as aortic valve insufficiency, gastrointestinal bleeding, pump thrombosis and hemolysis, cerebrovascular accident, renal dysfunction, and hypertension. Some of these could be related to reduced pulsatility of the arterial pressure [1] [2] [3] [4] .
There has been significant interest in evaluating the impact of generating pulsatile flow with continuous-flow pumps using speed modulation. The Cleveland Clinic continuous-flow total artificial heart (CFTAH) offers a unique platform, because its operation can range from completely nonpulsatile flow at constant speed to pulsatile flow during speed modulations. The purpose of this study was to evaluate the effects of sinusoidal pump speed modulation Abstract The purpose of this study was to evaluate the effects of sinusoidal pump speed modulation of the Cleveland Clinic continuous-flow total artificial heart (CFTAH) on hemodynamics and pump flow in an awake chronic calf model. The sinusoidal pump speed modulations, performed on the day of elective sacrifice, were set at ±15 and ± 25% of mean pump speed at 80 bpm in four awake calves with a CFTAH. The systemic and pulmonary arterial pulse pressures increased to 12.0 and 12.3 mmHg (±15% modulation) and to 15.9 and 15.7 mmHg (±25% modulation), respectively. The pulsatility index and surplus Artificial Heart (Basic) Coauthors 
Materials and methods

Pump description
The CFTAH delivers blood flow to both the systemic and pulmonary circulation from a single pump assembly (one motor with one rotating assembly supported on a hydrodynamic bearing) [5, 6] . Impellers supporting the left and right circulation are mounted on the two ends of the single rotating assembly, which is free to move axially, allowing the left and right hydraulic environments to create opposing forces at opposite ends of the rotor. Features of a pressure regulator are integrated into the pumping element design to passively self-balance left and right flows and atrial pressures. The nominal external dimensions of the latest CFTAH design used in these studies are 98.4 mm (length), 62 mm (diameter), 160 ml (volume displacement), and 486 g (device weight with cable and connector off the scale) (Fig. 1a, b) . 
In Vivo Study
The CFTAH was implanted in four Jersey calves (weight range 77.0-93.9 kg) by resecting both ventricles under general anesthesia and cardiopulmonary bypass support [7] . Post implant, animals were transferred to the chronic care unit for postoperative care under continuous hemodynamic monitoring. The systemic arterial pressure (AoP, obtained from a catheter within the carotid artery) and pulmonary arterial pressure (PAP) were continuously monitored with fluid-filled pressure lines. Instantaneous pump flow was calculated from the pump speed and motor power [5] .
The pump speed modulation study was performed on the day of elective sacrifice in four animals that had been living with the implanted CFTAH for the planned duration of 14 (one animal), 30 (one animal), or 90 days (2 animals). The sinusoidal pump speed modulations were performed at ±15% and ±25% of mean pump speed at 80 bpm for about 10 min each, similar to what we reported in acute anesthetized calves [6] . Due to voltage limitations of the current controller, the maximum pump speed was truncated at 3600 rpm when ±25% of speed modulation was used. The hemodynamics (AoP, PAP, and pump flow) were evaluated and compared to the constant speed (0% modulation) condition. The pulsatility index was calculated by the difference between the peak and minimum pump flow rates divided by the mean pump flow rate. To further evaluate pulsatility, the energy-equivalent pressure (EEP) and surplus hemodynamic energy (SHE) were calculated using the formulas EEP = ∫ Q × AoP dt∕ ∫ Q dt and SHE = 1332 × (EEP− mean AoP) (Q is the instantaneous pump flow) [8] .
The study was approved by Cleveland Clinic's Institutional Animal Care and Use Committee, and the animals received humane care in compliance with the "Guide for the Care and Use of Laboratory Animals" (Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, National Academy Press, Washington, DC 2011) and institutional policy on animal care. Figure 1c shows representative waveforms of pump speed, AoP, and pump flow with sinusoidal pump speed modulations of 0, ±15, and ±25%. With ±15 and ±25% speed modulations, the pump flow waveform and the AoP waveform showed higher pulsatility than those with no speed modulation. The AoP and PAP pulse pressures increased to 12.0 ± 4.1 and 12.3 ± 0.5 mmHg at ±15% speed modulation and to 15.9 ± 5.3 and 15.7 ± 0.8 mmHg at ±25% speed modulation, respectively ( Table 1 ). The first derivative (dP/ dt) of the AoP significantly increased to 121 ± 28 mmHg at 25% speed modulation. The pulsatility index and SHE significantly increased to 1.05 ± 0.14 and 1346 ± 479 ergs/ cm at ±15% speed modulation and to 1.51 ± 0.20 and 3381 ± 1477 ergs/cm at ±25% speed modulation. There were no changes in the mean AoP, mean PAP, or mean pump flow. The calves showed no behavioral changes during the pump speed modulation study.
Results
Discussion
In this study, we demonstrated the feasibility of generating pulsatility with pump speed modulations of the CFTAH in chronic, awake, upright calves with normal sympathetic tone, confirming the results of our earlier study, performed as an open-chest procedure in acute anesthetized calves in which the sympathetic system had been dampened [6] . The augmentation in pulsatility was low (pulse pressure of 15.9 mmHg, pulsatility index of 1.51, and SHE of 3381 ergs/cm at ±25% modulation) probably due to (1) low flow modulation compared with the native heart and (2) higher vascular compliance of the calves. Only sinusoidal pump speed modulations at 80 bpm were evaluated; however, as we previously demonstrated in vitro [9] , a wide variety of pulsatilty can be generated with this device, including physiologic pulsation. There was some pulsatility observed at 0% speed modulation (pulse pressure of 5.6 and 9.6 mmHg in AoP and PAP, respectively). In these chronic calves with the CFTAH, the left and right atria were preserved and beating. This atrial kick, in addition to respiratory effects, caused some pulsatility even with 0% speed modulation, as shown in Fig. 1c .
Our group was the first (in the 1980s) to demonstrate the feasibility of nonpulsatile circulation, reporting 3-month survival in animals with a fibrillated heart totally supported by two external centrifugal pumps [10, 11] . Since then, the effects of reduced pulsatility have been a subject of debate [12] [13] [14] [15] , which has recently taken on more urgency in a new era of increased use of CF LVADs as destination therapy. A critical issue in evaluating the effects of pulsatility is lack of a chronic, implantable device that can produce all the following conditions: no pulse, various degrees of pulsatility, and "physiological pulsatility" (a pulse pressure of ~40 mmHg with no flow during two-thirds of the cardiac cycle). The CFTAH has the ability to produce totally nonpulsatile flow (constant speed without speed modulation), various degrees of pulsatility (sinusoidal speed modulation of ±15, ±25, and ± 35% of mean speed), and physiological pulse (with optimized speed modulation to mimic physiological pulse [9] ). Therefore, this CFTAH gives us a unique opportunity to directly evaluate the effects of different pulsatility with the same device in the same animal.
A limitation of this study is the very short duration (about 10 min) of each speed modulation, focusing only on the immediate hemodynamic changes. End-organ function, hemolysis, microcirculation, or histopathology were not evaluated during these hemodynamic conditions and remain to be explored. There is a potential for CFTAH speed modulation to be evaluated clinically for its impact on the severity of potential complications from chronic depulsed circulation. Speed modulation may also show an advantage in terms of biocompatibility by eliminating areas of fixed low velocity and/or high residence time within the device and its conduits by inducing time-varying pulsatile pressure and blood-velocity profiles.
Conclusions
The feasibility of generating pressure pulsatility with pump speed modulation of the CFTAH was validated. This unique platform is suitable for evaluating the physiologic impact of pulsatility and allows determination of the best speed modulations in terms of magnitude, frequency, and profiles.
